Business
Candel Therapeutics Sets Stage For Success With Cancer-Fighting Immunotherapies
--News Direct--By Jeremy Golden, BenzingaA clinical-stage biopharmaceutical company looks forward to the year ahead with several promising developments in
About this update from Candel Therapeutics, Inc.
[{"type":"text","content":"--News Direct--By Jeremy Golden, BenzingaA clinical-stage biopharmaceutical company looks forward to the year ahead with several promising developments in motion. Focused on the development of multimodal biological immunotherapies to help patients fight cancer, Candel Therapeutics, Inc. (NASDAQ: CADL) is innovating a new frontier in the field of immunotherapy. By leveraging a data-driven approach, the company seems poised to advance next-generation immunotherapies in its pipeline as well as create new product candidates.Following up on promising initial clinical and biomarker data in hard-to-treat cancers, Candel is moving forward with a focus on strategic key value drivers and catalysts. Lead Candidates Based in Needham, Massachusetts, Candel is developing two off-the-shelf clinical-stage investigational viral immunotherapies. Designed to elicit an individualized anti-cancer response, they are based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. CAN-2409 is the lead product candidate from the adenovirus platform. It’s in the midst of ongoing late-stage clinical trials in non-small cell lung cancer (NSCLC) (phase 2), borderline resectable pancreatic cancer (phase 2) and localized, non-metastatic prostate cancer (phase 2 and 3).CAN-3110 is the lead product candidate from the HSV platform. A phase 1 clinical trial in recurrent high-grade glioma (HGG) is currently ongoing. Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform that leverages human biology and advanced analytics to create new viral immunotherapies for solid tumors.The year 2023 was a productive one for Candel. The company received Fast Track Designation from the FDA based on encouraging clinical activity and biomarker data from the phase 2 clinical trial of CAN-2409 in NSCLC, was also granted Fast Track Designation based on the positive interim data from the ongoing randomized phase 2 clinical trial in borderline resectable pancreatic cancer, published the activity of CAN-3110 in recurrent high-grade glioma in Nature and presented data on the first molecule that was discovered based on the enLIGHTENTM Discovery Platform at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC).In NSCLC, the phase 2 clinical trial showed that experimental therapy with CAN-24...